Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome

Thrombosis and Haemostasis

Volumn 114, Issue 4, 2015, Pages 702-707

  Bonello, Laurent ^a,b   Laine, Marc ^a   Camoin Jau, Laurence ^c   Noirot, Frederic ^a   Guieu, Régis ^d   Dignat George, Françoise ^b,e   Paganelli, Franck ^a   Frere, Corinne ^b,c  

^a HÔPITAL NORD   (France)

^b INSERM   (France)

^c TIMONE HOSPITAL   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

Author keywords

P2Y12 ADP receptor; Pretreatment; Thrombosis; Vasodilator phophoprotein

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; P2Y12 ADP RECEPTOR BLOCKING AGENT; PRASUGREL; RECEPTOR BLOCKING AGENT; TICAGRELOR; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ADENOSINE; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; P2RY12 PROTEIN, HUMAN; PHOSPHOPROTEIN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MEDICATION COMPLIANCE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; ACUTE CORONARY SYNDROME; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECTS; FRANCE; METABOLISM; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; TIME FACTOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; BIOMARKERS; BLOOD PLATELETS; CELL ADHESION MOLECULES; FRANCE; HUMANS; MICROFILAMENT PROTEINS; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TIME FACTORS; TREATMENT OUTCOME;

EID: 84943193127     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-02-0149     Document Type: Article

References (23)

1. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-109.
2. Mehta SR, Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000; 21: 2033-2041.
3. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111: 2560-2564.
4. Tantry US, Bonello L, Aradi D, et al. Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischaemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
5. Steinhubl SR, Berger PB, Mann JT 3rd, et al. CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Clopidogrel for the Reduction of Events During Observation. J Am Med Assoc 2002; 288: 2411-2420.
6. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619.
7. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
8. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
9. Bellemain-Appaix A, O’Connor SA, Silvain J, et al.; ACTION Group. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Am Med Assoc 2012; 308: 2507-2516.
10. Montalescot G, Bolognese L, Dudek D, et al. ACCOAST Investigators. Pre-treatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010.
11. ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-1027.
12. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-1606.
13. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797-804.
14. Barragan P, Paganelli F, Camoin-Jau L, et al. Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity. Thromb Haemost 2010; 104: 410-411.
15. Abtan J, Silvain J, Kerneis M, et al. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. Thromb Haemost 2013; 110: 1055-1064.
16. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
17. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
18. Bonello L, Berbis J, Laine M, et al. Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. Thromb Haemost 2012; 108: 101-106.
19. Frelinger AL 3rd, Michelson AD, Wiviott SD, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite highlevel P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106: 219-226.
20. Alexopoulos D. P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: fighting against the activated platelets. Int J Cardiol 2013; 163: 249-255.
21. Lakkis N, Dokainish H, Abuzahra M, et al. Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 2004; 4: 2091-2093.
22. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2014; Epub ahead of print.
23. Lemesle G, Schurtz G, Bauters C, et al. High on-treatment platelet reactivity with Ticagrelor versus Prasugrel: a systematic review and meta-analysis. J Thromb Haemost 2015; Epub ahead of print.